REG - e-Therapeutics plc - Notice of AGM and Posting of Annual Report

E-TherapeuticsAnnouncement

11/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230511:nRSK0085Za&default-theme=true

RNS Number : 0085Z  e-Therapeutics plc  11 May 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Notice of Annual General Meeting and Posting of Annual Report and Accounts
 

 

 

London, UK, 11 May 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that its Annual Report and
Accounts for the year ended 31 January 2023, which includes the notice of its
2023 Annual General Meeting ("AGM") have been posted to shareholders today and
are available on the Company's website at:

 

https://www.etherapeutics.co.uk/application/files/9516/8317/9500/ETX_Annual_Report_2023.pdf
(https://www.etherapeutics.co.uk/application/files/9516/8317/9500/ETX_Annual_Report_2023.pdf)

 

The AGM will be held at 12:30p.m. on 18 July 2023 at 4 Kingdom Street,
Paddington, London, W2 6BD.

 

The right to attend and vote at the  AGM is determined by reference to the
Company's register of members.  Only a member entered in the register of
members as at close of business on 14 July 2023 (or, if the AGM is adjourned,
in the register of members as at the close of business on the date which is
two business days before the time of the adjourned  AGM) is entitled to
attend and vote at the  AGM.

 

Shareholders who wish to register their votes on the resolutions to be put to
the AGM should do so by completing and signing the proxy form that accompanies
the notice of the AGM (or appoint a proxy electronically if their shares are
held in CREST) in accordance with the instructions printed on the proxy form.

 

Please complete and return the form of proxy in accordance with the
instructions printed thereon as soon as possible and, in any event, so that it
is received by the Company's registrar, Neville Registrars Limited, Neville
House, Steelpark Road, Halesowen, B62 8HD not later than 12:30p.m. on 14 July
2023.

 

If you do not have a proxy form and believe that you should have one, or if
you have any additional queries on voting, please contact Neville Registrars
Limited.

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                                                 Tel: +44 (0)20 4551 8888

 Laura Roca-Alonso, COO/CBO                                                         www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)

      SP Angel Corporate Finance LLP                                                Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary HepNet(TM) platform enables the generation and analysis of
biological network models, providing a novel and mechanistic approach to drug
discovery. This approach explicitly considers the true complexity of biology
to make more reliable predictions from large complex data sets and ETX's
proprietary hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource.  The Company generates,
prioritises and tests millions of hypotheses in silico to identify better
therapeutic targets with higher confidence.

 

GalOmic(TM), ETX's proprietary RNAi platform, enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by HepNet(TM).  The focus on hepatocytes
offers the opportunity to tackle a wide variety of diseases.  The liver is a
highly metabolically active organ which performs a key role in many biological
processes and vital functions crucial for human health. ETX's GalOmic(TM)
constructs have demonstrated compelling in vivo performance in terms of
depth of gene silencing and duration of action.

 

The Company is progressing a pipeline of first-in-class preclinical RNAi
candidates across several high unmet medical needs in cardiometabolic
indications and targeting promising hepatocyte-expressed targets with effects
in other disease areas. ETX has also partnered with biopharma companies such
as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational
network biology approach across a diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAAMMFTMTJBBMJ